First Patient Dosed with ELU001 in Expansion Cohort of Ph 1/2 Trial
“This is a notable milestone for the company, as we continue to progress our lead CDC candidate, ELU001, in this important Phase 1/2 trial. The safety data to date has been differentiating for ELU001 when compared to ADCs, including those targeting the same folate receptor alpha target, and we look forward to presenting ELU001 clinical data at a major medical conference later this year,” stated Geno Germano, President and CEO of Elucida Oncology.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.